Related references
Note: Only part of the references are listed.Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Carsten U. Niemann et al.
BLOOD (2021)
Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML
Si Li et al.
BIOORGANIC CHEMISTRY (2021)
Ibrutinib's off-target mechanism: cause for dose optimization
Sara M. Zimmerman et al.
CANCER BIOLOGY & THERAPY (2021)
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
PROTACs to address the challenges facing small molecule inhibitors
Pedro Martin-Acosta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of novel BTK PROTACs for B-Cell lymphomas
Yunpeng Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase
Dandan Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel BTK mutation in X-linked agammaglobulinemia: Report of a 17-year-old male
Zoha Shaka et al.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2021)
1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase
Sona Krajcovicova et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development
Jiakuo Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupinan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
Logan Good et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma
Fansheng Ran et al.
BIOORGANIC CHEMISTRY (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
Simo Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
Xiuyun Sun et al.
BIOCHEMISTRY (2020)
Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
Fansheng Ran et al.
BIOORGANIC CHEMISTRY (2020)
The role of MYC in the transformation and aggressiveness of ?indolent? B-cell malignancies
Daniel Filip et al.
LEUKEMIA & LYMPHOMA (2020)
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Ola A. Elgamal et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Xu-Wen Guan et al.
CELL DEATH & DISEASE (2020)
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Peter Hillmen et al.
FUTURE ONCOLOGY (2020)
Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
Ronen Gabizon et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Bhawana George et al.
CANCERS (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
H. Yesid Estupinan et al.
BLOOD ADVANCES (2020)
PROTAC: A promising technology for cancer treatment
Xin Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
Laura Ondrisova et al.
FRONTIERS IN ONCOLOGY (2020)
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Yuqin Song et al.
BLOOD (2020)
In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, Rituximab, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice
Eliana B. Gomez et al.
BLOOD (2020)
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Anthony R. Mato et al.
BLOOD (2020)
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor et al.
CELL DEATH & DISEASE (2020)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin et al.
BLOOD (2019)
Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
Yifan Feng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL
Fansheng Ran et al.
BIOORGANIC CHEMISTRY (2019)
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
Chufeng Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting BTK in CLL: Beyond Ibrutinib
David A. Bond et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies
Fu Gui et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines
Xiaofeng Guo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
Sayan Dutta Gupta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of targeted protein degradation therapeutics
Philip P. Chamberlain et al.
NATURE CHEMICAL BIOLOGY (2019)
Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
Eliana B. Gomez et al.
BLOOD (2019)
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Jennifer Woyach et al.
BLOOD (2019)
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Bartosz Pula et al.
CANCERS (2019)
Gambogic acid induces heme oxygenase-1 through Nrf2 signaling pathway and inhibits NF-κB and MAPK activation to reduce inflammation in LPS-activated RAW264.7 cells
Jie Ren et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
Isha Kapoor et al.
CELL DEATH & DISEASE (2019)
Bruton Tyrosine Kinase Inhibitors Present and Future
Jan A. Burger
CANCER JOURNAL (2019)
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E. Coutre et al.
BLOOD ADVANCES (2019)
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
Zhen Zhang et al.
ARCHIV DER PHARMAZIE (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
Sean D. Reiff et al.
BLOOD (2018)
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
Ann E. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Kelly Valla et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
Linyi Liu et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
Gabriela Pavlasova et al.
LEUKEMIA (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C. Byrd et al.
Oncotarget (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma
Sudharshan Eathiraj et al.
CANCER RESEARCH (2018)
Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
Ana Colado et al.
BLOOD CANCER JOURNAL (2018)
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
Allard Kaptein et al.
BLOOD (2018)
Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia
Valeria Spina et al.
BLOOD (2018)
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
Jimmy Lee et al.
BLOOD ADVANCES (2018)
Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines
Dan Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
He Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
J. Deng et al.
LEUKEMIA (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition
Gabriele Varano et al.
NATURE (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
Anella Yahiaoui et al.
PLOS ONE (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase
Catherine A. Fabian et al.
CANCER RESEARCH (2017)
Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
Preetesh Jain et al.
CANCER (2017)
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Stephen K. Tahir et al.
BMC CANCER (2017)
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski et al.
CLINICAL CANCER RESEARCH (2016)
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
Adam R. Johnson et al.
ACS CHEMICAL BIOLOGY (2016)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
E. Gaudio et al.
ANNALS OF ONCOLOGY (2016)
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Caron Jacobson et al.
BLOOD (2016)
Targeting BTK through microRNA in chronic lymphocytic leukemia
A. Bottoni et al.
BLOOD (2016)
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis
Gabriela Pavlasova et al.
BLOOD (2016)
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
David E. Spaner et al.
HAEMATOLOGICA (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Approaching resistance to ibrutinib in diffuse large B-cell lymphoma
Tabea Erdmann et al.
LEUKEMIA & LYMPHOMA (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Atish Mohanty et al.
ONCOTARGET (2016)
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
David E. Spaner et al.
HAEMATOLOGICA (2016)
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
Matthew S. Davids et al.
BLOOD (2016)
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line
Kazumi Hagiwara et al.
APOPTOSIS (2015)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sutapa Sinha et al.
CLINICAL CANCER RESEARCH (2015)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
Perfluorooctane sulfonate mediates microglial activation and secretion of TNF-α through Ca2+-dependent PKC-NF-κB signaling
Jianbin Yang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
Stuart A. Rushworth et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Src family kinases: at the forefront of platelet activation
Yotis A. Senis et al.
BLOOD (2014)
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Jiao Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis
Jennifer A. Whang et al.
DRUG DISCOVERY TODAY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients
J. Boysen et al.
LEUKEMIA (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Celastrol Induces Apoptosis of Gastric Cancer Cells by miR-21 Inhibiting PI3K/Akt-NF-kappa B Signaling Pathway
Min Sha et al.
PHARMACOLOGY (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib
Chung-Shien Lee et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Ibrutinib and novel BTK inhibitors in clinical development
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Inhibition of NF-κB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury
Jin-Hua Gu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Tyrosine Kinase Btk Is Required for NK Cell Activation
Yan Bao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
Hsp90 and Co-Chaperones Twist the Functions of Diverse Client Proteins
Abbey Zuehlke et al.
BIOPOLYMERS (2010)
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
J. Michael Bradshaw
CELLULAR SIGNALLING (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa et al.
BLOOD (2009)
Vorinostat in solid and hematologic malignancies
David Siegel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Norihiko Kawamata et al.
BLOOD (2007)
Share Paper
